Plasma gonadotropin response to D-Ala6-LH-RH propylamide

Area of Science:

• Endocrinology
• Reproductive Medicine
• Pharmacology

Background:

• Amenorrhea, a condition characterized by the absence of menstruation, can stem from various hormonal imbalances.
• Previous diagnostic tests including urinary steroid secretion, progesterone challenge, clomiphene, human menopausal gonadotropin (HMG), and LH-RH tests were performed.
• Understanding the hormonal milieu is crucial for managing reproductive health disorders.

Purpose of the Study:

• To evaluate the effects of a long-acting analog of LH-RH, D-Ala6-desGly10-LH-RH propylamide (D-Ala6-LH-RH PA), on luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels.
• To assess the safety and hormonal response profile of D-Ala6-LH-RH PA in women with amenorrhea.

Main Methods:

• Intramuscular administration of 250 micrograms of D-Ala6-LH-RH PA to 11 women diagnosed with amenorrhea.
• Serial blood sampling at multiple time points (0.5 to 32 hours post-injection) to measure plasma LH and FSH levels.
• Radioimmunoassays were utilized for precise quantification of LH and FSH concentrations.

Main Results:

• D-Ala6-LH-RH PA induced a substantial increase in both plasma LH and FSH levels.
• Maximal LH increase ranged from 220% to 4,300%, with peak levels observed between 0.5 and 12 hours.
• Maximal FSH increase ranged from 63% to 1,442%, typically peaking between 4 and 8 hours.
• No adverse side effects were reported during the study period.

Conclusions:

• The long-acting LH-RH analog, D-Ala6-LH-RH PA, demonstrates potent stimulatory effects on gonadotropin release (LH and FSH).
• This analog shows potential for therapeutic applications in conditions requiring modulation of the hypothalamic-pituitary-gonadal axis.
• Further research is warranted to explore its clinical utility in managing specific reproductive endocrine disorders.